-

05:44:11 PM

CDTX Stock News

CDTX - Cidara Therapeutics Inc

05/11/23 4:37 PM

Nasdaq : CDTX

earnings

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter

RHEA-AI

neutral

05/03/23 4:30 PM

Nasdaq : CDTX

clinical trial

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and

RHEA-AI

neutral

04/24/23 8:00 AM

Nasdaq : CDTX

fda approval

Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™

RHEA-AI

very positive

03/31/23 8:00 AM

Nasdaq : CDTX

conferences

Cidara Therapeutics to Participate in Upcoming Investor Conferences

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief

RHEA-AI

neutral

03/23/23 7:12 AM

Nasdaq : CDTX

earnings

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full

RHEA-AI

positive

03/22/23 5:23 PM

Nasdaq : CDTX

fda approval

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO is the first new FDA-approved echinocandin in over a decade – SAN DIEGO and PARSIPPANY, N.J.,

RHEA-AI

very positive

03/07/23 4:15 PM

Nasdaq : CDTX

clinical trial

Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, presented preclinical data on a CD73-targeting drug-Fc conjugate

RHEA-AI

neutral

03/07/23 4:01 PM

Nasdaq : CDTX

offering

Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares in Public Offering of Common Stock

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced

RHEA-AI

neutral

03/03/23 9:14 AM

Nasdaq : CDTX

offering

Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate

RHEA-AI

neutral

03/02/23 4:14 PM

Nasdaq : CDTX

offering

Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced concurrent but separate underwritten public

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

CDTX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitecidara.com
CeoJeffrey Stein
Security nameCidara Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees89
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address6310 Nancy Ridge Dr Ste 101
StateCalifornia
CitySan Diego
Zip92121-3209
CountryUS
Phone18587526170

About Cidara Therapeutics Inc

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.